Troy Tyner
Internal Medicine · Beavercreek, OHNPI 1003814526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,224, 8.6 times the $143 reported in 2019.
Across 186 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$425
- Dexcom, Inc.$385
- Novo Nordisk$304
- Boehringer Ingelheim$297
- Abbott$281
- AbbVie$247
- plus $2K from 24 others
Across 49 payments — averaging $6278.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acella Pharmaceuticals, LLC$137K
- AstraZeneca$131K
- Alnylam Pharmaceuticals Inc.$22K
- Avion Pharmaceuticals$17K
What the payments were for
- Food & beverage$3,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $425 |
| Dexcom, Inc. | 6 | $385 |
| Novo Nordisk | 18 | $304 |
| Boehringer Ingelheim | 18 | $297 |
| Abbott | 14 | $281 |
| AbbVie | 12 | $247 |
| AstraZeneca | 14 | $229 |
| Lilly USA, LLC | 13 | $211 |
| Amgen | 11 | $189 |
| Bayer | 10 | $169 |
| Corcept Therapeutics | 8 | $148 |
| E.r. Squibb & Sons, L.L.C. | 2 | $104 |
| Aimmune Therapeutics, Inc. | 5 | $86 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Merck | 5 | $75 |
| Amneal Pharmaceuticals LLC | 5 | $71 |
| Zealand Pharma US, Inc. | 3 | $63 |
| Tandem Diabetes Care, Inc. | 5 | $56 |
| Exact Sciences | 2 | $55 |
| Pfizer | 3 | $50 |
| Mannkind Corporation | 2 | $47 |
| Johnson & Johnson | 3 | $42 |
| Novartis | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Cequr Corporation | 1 | $31 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Lifescan, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 2 | $11 |
| Clarus Therapeutics Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,807 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $31,956 |
| EliquisApixaban | 13 | $14,094 |
| FarxigaDapagliflozin Propanediol | 16 | $12,301 |
| JanuviaSitagliptin Phosphate | 11 | $12,033 |
| Testosterone | 19 | $1,578 |
| Hydrocortisone | 21 | $1,286 |
| Levothyroxine Sodium | 85 | $986 |
| Omeprazole | 35 | $663 |
| Atorvastatin Calcium | 62 | $479 |
| Gabapentin | 24 | $459 |
| Losartan Potassium | 33 | $367 |
| Lisinopril | 53 | $323 |
| Spironolactone | 26 | $322 |
| Pantoprazole Sodium | 31 | $226 |
| Amlodipine Besylate | 30 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $304 | $31,95625 claims |
| PfizerEliquis | $50 | $14,09413 claims |
| AstraZenecaFarxiga | $229 | $12,30116 claims |
| MerckJanuvia | $75 | $12,03311 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $98685 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Beavercreek
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.